Maze Therapeutics (NASDAQ:MAZE) Trading Down 5.8% – Should You Sell?

Posted by Stanley Muller on Aug 31st, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report)’s share price dropped 5.8% during mid-day trading on Monday . The stock traded as low as $25.85 and last traded at $25.85. 203,386 shares traded hands during trading, a decline of 68% from the average daily volume of 642,078 shares. The stock had previously closed at $27.44.

Analyst Ratings Changes

A number of research firms have recently issued reports on MAZE. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen cut shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, TD Cowen raised Maze Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus target price of $66.00.

Check Out Our Latest Stock Analysis on Maze Therapeutics

Maze Therapeutics Trading Down 5.6%

The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. The business’s 50-day moving average is $28.74 and its 200 day moving average is $31.79. The firm has a market capitalization of $1.44 billion, a P/E ratio of -10.28 and a beta of 2.22.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.76). As a group, analysts anticipate that Maze Therapeutics, Inc. will post -2.72 EPS for the current fiscal year.

Insider Activity

In other news, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider owned 26,250 shares in the company, valued at approximately $717,675. This represents a 22.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the completion of the sale, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. This trade represents a 59.65% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 108,110 shares of company stock valued at $3,057,531. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Institutional investors have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Maze Therapeutics in the 4th quarter worth approximately $43,000. California State Teachers Retirement System grew its stake in shares of Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics during the second quarter valued at $48,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter.

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.